內容目錄

Toggle

New Obesity Drug, Belviq, in US Pharmacies Next Week

Lisa Nainggolan

Jun 07, 2013

The new obesity drug lorcaserin (Belviq, Eisai/Arena Pharmaceuticals) will finally be available for prescription in the United States next week, the manufacturers have announced. The news comes as the European regulatory agency provides more details about why it rejected the product.

Lorcaserin, which was cleared for marketing in the United States almost a year ago in its second attempt, is indicated for chronic weight management, along with a calorie-controlled diet and increased physical activity, in adults with a body mass index (BMI) of 30 kg/m² more or in those with a BMI of 27 kg/m²or more who have at least 1 weight-related medical condition, such as type 2 diabetes or high blood pressure.

Lorcaserin is a 5HT2c-receptor agonist, which is believed to imitate the effects of serotonin on these receptors, resulting in an increased sense of fullness after a meal and reduced hunger before meals, thereby reducing food consumption.消息來源

孫銘聰醫師comment: 看來近年來第二個核准的專用減肥藥Lorcaserin，商品名Belviq也要在美國上市了，僅僅與Qsymia差沒幾個月，要知道上次核准的專用減肥藥已經距今13年之久，連羅氏鮮都過專利期了~話說回來，簡介一下藥理機轉，此藥物作用於 central serotonergic pathways，是5HT2c-receptor agonist，可作用於中樞抑制食慾

作用與其他藥物比較一下

效果也比較一下~使用Lorcaserin 平均減8.2kg，相較於安慰劑組可減3.4kg而言，多減了4.8kg~不過也要澄清一下，不管藥物組或者安慰劑組在減肥研究時都還是要配合飲食、運動控制，並非單純吃藥而已喔，所以大家也是要記住，藥物只是輔助，還是以飲食、運動為主軸，才能有效控制體重!

其他相關文章：減肥新藥lorcaserin的現況